Hexagon Nutrition IPO: Why The Risks Matter More Than The Hype

Anirudh Jain - Kolkata Bureau Jun 02, 2026 1,700 Views

Hexagon Nutrition’s Rs 138.87 crore IPO opens this week with a price band of Rs 42 to 45 per share, structured as an offer for sale by existing shareholders. Early chatter around the issue and unofficial grey market activity is building, but serious investors should park the noise and focus on the risk sheet before subscribing.

The company operates in the nutrition and micronutrient solutions space, which sounds like a neat combination of healthcare and consumption. In practice, though, it is a more delicate business. Revenue concentration, regulatory exposure and the demands of contract manufacturing all sit close to the surface. For a relatively small, specialised player, the room for error is narrower than the marketing narrative suggests.

Key Risks Around The Business Model

Hexagon’s revenues lean on a limited set of customers and contracts, which means any strain in key relationships or pricing can hit growth abruptly. The company also works in a tightly regulated environment, spanning food safety, health norms and export rules, so compliance lapses can quickly turn into financial and reputational setbacks. Add raw material price swings and the need to keep innovating products, and maintaining steady margins becomes a constant balancing act.

Valuation, Market Mood And GMP Chatter

At the upper end of the price band, the implied valuation looks demanding for a business of this size and history, especially when larger, more established names in allied spaces are already listed. Unofficial grey market premium talk may surface closer to listing, but it is at best a sentiment indicator, not a promise of gains, in a market that has turned more selective on mid and small cap IPOs. Investors weighing the issue should match their risk appetite with the realities of regulation, execution and customer dependence, rather than relying solely on the broader “nutrition” theme.